XOMA Announces Transformational License Agreements for Gevokizumab and its IL-1 Beta Intellectual Property Portfolio
$31 million in upfront payments including $5 million equity investment 50 percent reduction in XOMA’s outstanding debt through repayment of its €12 million obligation to Les Laboratoires Servier Significant potential milestone payments plus tiered …